The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

Cigna To Reform Prior Authorization, Provider Services In 2025 The Cigna Group will spend up to $150 million to reform its prior authorization, patient advocacy and provider services this year, CEO ...

The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

Whether you’re cleaning your kitchen after a big meal or finishing a painting project, it can be tempting to pour just about ...

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction of a first-in-class non-opioi ...

The birth control drug name-dropped in Project 2025 is suddenly getting new attention, thanks to research suggesting it could ...

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

Medical cannabis became legal in Kentucky on Jan. 1 for patients meeting specific conditions, but don’t be fooled by the name — hospitals and traditional health facilities and pharmacies are not ...

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.